InvestorsHub Logo
Followers 3157
Posts 961381
Boards Moderated 204
Alias Born 09/04/2000

Re: mick post# 264

Tuesday, 07/28/2020 6:58:51 PM

Tuesday, July 28, 2020 6:58:51 PM

Post# of 956
$MATN - Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN).
https://finance.yahoo.com/news/company-expands-management-team-accelerate-110010416.html?.tsrc=rss

Agoura Hills, California, July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-ß inhibitor with the potential for multiple therapeutic indications including glioblastoma,
pancreatic cancer,
melanoma and COVID-19,
appointed Giancarlo Mennella,
Managing Director at EGAMID LTD,
to lead its licensing activity for Trabedersen (OT-101) for COVID-19 globally with emphasis on South America where the treatment for COVID-19 is especially needed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLC News